Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.10.2 (
focal adhesion kinase
)
44,029
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Triple negative breast cancer (TNBC) has poor survival, exhibits rapid metastases, lacks targeted therapies and reliable prognostic markers. Here, we examined metastasis promoting role of cancer testis antigen
SPANXB1
in TNBC and its utility as a therapeutic target and prognostic biomarker. Expression pattern of
SPANXB1
was determined using matched primary cancer, lymph node metastatic tissues and circulating small extracellular vesicles (sEVs). cDNA microarray analysis of TNBC cells stably integrated with a metastasis suppressor SH3GL2 identified
SPANXB1
as a potential target gene. TNBC cells overexpressing SH3GL2 exhibited decreased levels of both
SPANXB1
mRNA and protein. Silencing of
SPANXB1
reduced migration, invasion and reactive oxygen species production of TNBC cells.
SPANXB1
depletion augmented SH3GL2 expression and decreased RAC-1,
FAK
, A-Actinin and Vinculin expression. Phenotypic and molecular changes were reversed upon
SPANXB1
re-expression.
SPANXB1
overexpressing breast cancer cells with an enhanced
SPANXB1
:SH3GL2 ratio achieved pulmonary metastasis within 5 weeks, whereas controls cells failed to do so. Altered expression of
SPANXB1
was detected in the sEVs of
SPANXB1
transduced cells. Exclusive expression of
SPANXB1
was traceable in circulating sEVs, which was associated with TNBC progression.
SPANXB1
represents a novel and ideal therapeutic target for blocking TNBC metastases due to its unique expression pattern and may function as an EV based prognostic marker to improve TNBC survival. Uniquely restricted expression of
SPANXB1
in TNBCs, makes it an ideal candidate for targeted therapeutics and prognostication.
...
PMID:Cancer Testis Antigen Promotes Triple Negative Breast Cancer Metastasis and is Traceable in the Circulating Extracellular Vesicles. 3200 91